Bangalore, July 18, 2014
Infosys, a global leader in consulting, technology and outsourcing solutions, has been rated as a Leader and Star Performer in life sciences IT Outsourcing (ITO) in Everest Group’s report “IT Outsourcing in Life Sciences Industry – Service Provider Landscape with PEAK Matrix™ Assessment 2014.”
Infosys scored high in terms of the size and growth of its life sciences revenues in 2013, global delivery capability and overall market success. This was aided by investments in proprietary solutions and an expanding portfolio of offerings in the life sciences space. This portfolio includes solutions that support drug discovery, clinical trials, salesforce effectiveness, digital marketing, ERP, supply chain transformation, management of complex compliance processes and solutions to track and trace. Infosys’ clients in the sector include global and mid-sized pharmaceutical companies, biotech organizations, medical devices manufacturers, and drug distributors.
Manish Tandon, Executive Vice President and Global Head – Life Sciences & Services, Infosys
“The life sciences industry is operating in a very dynamic landscape today with heightened regulatory scrutiny, patent cliffs, and growing incidence of mergers and acquisitions. Technology can play an important role to help life sciences companies embrace these changes and stay competitive. For example, Infosys recently launched a cloud-based solution to help enterprises in this industry reduce costs of regulatory compliance and clinical trial management while accelerating business processes.”
Jimit Arora, Vice President at Everest Group
“The new surge in life sciences in ITO is driven by application portfolio modernization, infrastructure transformation, and analytics. Life sciences enterprises are increasingly looking at service providers that can provide a blend of traditional and next-generation services. In the past year, Infosys has made investments to create a balanced portfolio of offerings across traditional and next-generation services. This has resulted in significant market success in large life sciences ITO contracts for the company and contributed to the rating of Leader and Star Performer in the Everest Group PEAK Matrix™.”
The 2014 Everest Group PEAK Matrix™ for Life Sciences IT Outsourcing report evaluated 18 IT services providers, selected on the basis of their success in large life sciences ITO relationships. Service providers were grouped into three high-level categories based on their capability, service offerings and market success. The report assessed the 18 companies based on the quality of their disclosures and interviews, Everest Group Transaction Intelligence database and feedback from life sciences ITO buyers.
Infosys is a global leader in consulting, technology and outsourcing solutions. We enable clients, in more than 30 countries, to stay a step ahead of emerging business trends and outperform the competition. We help them transform and thrive in a changing world by co-creating breakthrough solutions that combine strategic insights and execution excellence.
Visit www.infosys.com to see how Infosys (NYSE: INFY), with US$8.25 billion in annual revenues and 160,000+ employees, is Building Tomorrow's Enterprise® today.
Certain statements in this release concerning our future growth prospects are forward-looking statements regarding our future business expectations intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2014 and on Form 6-K for the quarter ended December 31, 2013. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the Securities and Exchange Commission and our reports to shareholders. In addition, please note that the date of this press release is mentioned at the beginning of the release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the company unless it is required by law.
For further information, please contact: PR_Global@infosys.com